Skip to main content
Robert Lafyatis, MD, Rheumatology, Pittsburgh, PA

Robert A. Lafyatis MD


Professor, Medicine, Boston University School of Medicine

Join to View Full Profile
  • 3601 Fifth AvenuePittsburgh, PA 15213

  • Phone+1 412-647-0943

  • Fax+1 412-647-4050

Dr. Lafyatis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Rheumatology, 1986 - 1989
  • Wake Forest University Baptist Medical Center
    Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 1984 - 1986
  • Wake Forest University Baptist Medical Center
    Wake Forest University Baptist Medical CenterInternship, Internal Medicine, 1983 - 1984
  • University of Cincinnati College of Medicine
    University of Cincinnati College of MedicineClass of 1983

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2015 - 2026
  • MA State Medical License
    MA State Medical License 1994 - 2017
  • NC State Medical License
    NC State Medical License 1985 - 1999
  • MD State Medical License
    MD State Medical License 1986 - 1992
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Rheumatology
    American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

  • Fellow (FACR) American College of Rheumatology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis  
    Robert Lafyatis, Yuqing Zhang, Arthritis & Rheumatology

Press Mentions

  • Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Cutaneous Systemic Sclerosis Trial of AVID200, a Novel TGF-Beta 1 & 3 Inhibitor
    Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Cutaneous Systemic Sclerosis Trial of AVID200, a Novel TGF-Beta 1 & 3 InhibitorMarch 4th, 2019
  • Rapid Skin Improvement Seen After Treating Systemic Sclerosis Patients with Fresolimumab
    Rapid Skin Improvement Seen After Treating Systemic Sclerosis Patients with FresolimumabJune 22nd, 2015

Grant Support

  • E-Box Accessibility in Myofibroblasts in Pulmonary FibrosisUNIVERSITY OF PITTSBURGH AT PITTSBURGH2025–2028
  • E-Box Accessibility in Myofibroblasts in Pulmonary FibrosisUNIVERSITY OF PITTSBURGH AT PITTSBURGH2025–2028
  • Clinical-Translational Studies in Skin, Lung, and Vascular Complications in Systemic SclerosisUNIVERSITY OF PITTSBURGH AT PITTSBURGH2022–2027
  • Pathways regulating profibrotic macrophages in a novel explant model of systemic sclerosis-associated interstitial lung diseaseUNIVERSITY OF PITTSBURGH AT PITTSBURGH2024–2026
  • Molecular Basis for Altered Natural Killer Cells in Systemic Sclerosis associated-Interstitial Lung DiseaseUNIVERSITY OF PITTSBURGH AT PITTSBURGH2024–2026
  • Mapping Age-Related Changes in the LungOHIO STATE UNIVERSITY2019–2025
  • International Workshop On Scleroderma ResearchNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2012
  • Rheumatic Diseases Research Core CentersNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
  • Project 1 Biomarkers Of Disease Activity And Progression In Systemic SclerosisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
  • Niams: CortNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
  • Innate Immunity In Dermal Fibrosis And Systemic SclerosisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
  • Tenth International Workshop On Scleroderma Research - August 2-6,2008, CambridgeNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2008–2009
  • Microarray Biomarkers Of Disease Activity And Progression In Systemic SclerosisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2007–2009
  • Altered Elastogenesis By TSK Fibrillin-1 And In SSCNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2005–2009
  • Rituximab Treatment Of SclerodermaNational Center For Research Resources2007
  • International Workshop For Scleroderma ResearchNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2006
  • Immune Mediated Alterations In Connective TissueNational Center For Research Resources2006
  • Rituximab Treatment Of Scleroderma - An OPEN Label, Phase I StudyNational Center For Research Resources2005–2006
  • SWAP And SR Protein Regulation Of Alternaive SplicingNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1997
  • Autoimmunity To And MRNA Splicing Regulation By SWAPNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1995–1996

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: